Colorectal cancer program quality

Quality can and should be measured

Through the accreditation process, quality is measured by compliance with standards. These standards are developed by national experts in colon and rectal cancer. They measure how well a program delivers the treatments that are proven to work the best.

Percent of the time our program meets or exceeds the highest national standards

Legacy Cancer Institute is shown in the blue bars on the left. Our performance exceeds our peers in all three quality measures. 

Chemotherapy for colorectal cancer that has spread to the lymph nodes

Legacy: 100%; accredited programs nationally: 88.6%

The goal is 100%.

Legacy (blue): 100%
Pacific region: 86.4%
Nationwide: 86.6%

Quality measure details: Adjuvant chemotherapy is considered or administered within 120 days of diagnosis for patients under age 80 with AJCC Stage III (lymph node positive) colon cancer.

Enough lymph nodes are removed and examined in patients who have surgery

Legacy: 94.7%; accredited programs nationwide: 87.7%
 
The goal is 100%.

Legacy (blue): 94.7%
Pacific region: 87.9%
Nationwide: 87.7%

Quality measure details:At least 12 lymph nodes are removed and pathologically examined for resected colon cancer.

Radiation therapy for certain patients who have surgery

Legacy: 100%; accredited programs nationally: 92.8%
 
The goal is 100%.

Legacy (blue): 100%
Pacific region: 92.3%
Nationwide: 92.8%

Quality measure details: Radiation therapy is considered or administered within 180 days of diagnosis for patients under age 80 and with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer.